Celldex Therapeutics Inc (CLDX) Unusual Options Activity Today

Checking CLDX unusual options activity helps you spot when traders are making outsized bets on Celldex Therapeutics Inc before the broader market catches on. Celldex Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor CLDX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching CLDX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CLDX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and CLDX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.

The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Catalysts rarely arrive without a footprint, and CLDX unusual options activity is often where that footprint shows up first. Our scanner tracks Celldex Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at CLDX unusual options volume on the call side or chasing put sweeps, Celldex Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.